Table 5.14: TDR Modifications

	Primary modification type (1) Financial effec							ts of modifications	
(\$ in millions)		Principal forgiveness	Interest rate reduction	Other concessions (2)	Total	Charge- offs (3)	Weighted average interest rate reduction	in int	Recorded nvestment related to cerest rate luction (4)
Year Ended December 31, 2022									
Commercial and industrial	\$	24	24	349	397	_	10.69%	\$	24
Commercial real estate		_	12	112	124	_	0.92		12
Lease financing		_	_	2	2		_		
Total commercial		24	36	463	523		7.51		36
Residential mortgage		1	369	1,357	1,727	6	1.61		369
Credit card		_	311	_	311	_	20.33		311
Auto		2	7	63	72	16	4.33		7
Other consumer		_	19	3	22	1	11.48		19
Trial modifications (5)				228	228		_		
Total consumer		3	706	1,651	2,360	23	10.14		706
Total	\$	27	742	2,114	2,883	23	10.02%	\$	742
Year Ended December 31, 2021									
Commercial and industrial	\$	2	9	879	890	20	0.81%	\$	9
Commercial real estate		41	15	259	315	_	1.28		14
Lease financing		_	_	7	7		_		
Total commercial		43	24	1,145	1,212	20	1.11		23
Residential mortgage		_	70	1,324	1,394	3	1.80		70
Credit card		_	106	_	106	_	19.12		106
Auto		1	4	131	136	54	3.82		4
Other consumer		_	18	1	19	_	11.83		18
Trial modifications (5)		_		(3)	(3)		_		_
Total consumer		1	198	1,453	1,652	57	12.01		198
Total	\$	44	222	2,598	2,864	77	10.84%	\$	221
Year Ended December 31, 2020									
Commercial and industrial	\$	24	47	2,971	3,042	162	0.74%	\$	48
Commercial real estate		10	35	684	729	5	1.11		35
Lease financing				1	1		_		_
Total commercial		34	82	3,656	3,772	167	0.90		83
Residential mortgage		_	25	4,277	4,302	7	1.93		51
Credit card		-	272	_	272	_	14.12		272
Auto		4	6	166	176	93	4.65		ε
Other consumer		_	23	34	57	1	8.28		23
Trial modifications (5)				3	3		_		_
Total consumer		4	326	4,480	4,810	101	11.80		352
Total	\$	38	408	8,136	8,582	268	9.73%	\$	435

⁽¹⁾ Amounts represent the recorded investment in loans after recognizing the effects of the TDR, if any. TDRs may have multiple types of concessions, but are presented only once in the first modification type based on the order presented in the table above. The reported amounts include loans remodified of \$445 million, \$737 million, and \$1.5 billion for the years ended December 31, 2022, 2021 and 2020, respectively.

⁽²⁾ Other concessions include loans with payment (principal and/or interest) deferral, loans discharged in bankruptcy, loan renewals, term extensions and other interest and noninterest adjustments, but exclude modifications that also forgive principal and/or reduce the contractual interest rate. The reported amounts include loans that are new TDRs that may have COVID-19-related payment deferrals and exclude COVID-19-related payment deferrals on loans previously reported as TDRs given limited current financial effects other than payment deferral.

deferrals and exclude COVID-19-related payment deferrals on loans previously reported as TDRs given limited current financial effects other than payment deferral.

(3) Charge-offs include write-downs of the investment in the loan in the period it is contractually modified. The amount of charge-off will differ from the modification terms if the loan has been charged down prior to the modification based on our policies. In addition, there may be cases where we have a charge-off/down with no legal principal modification.

⁽⁴⁾ Recorded investment related to interest rate reduction reflects the effect of reduced interest rates on loans with an interest rate concession as one of their concession types, which includes loans reported as a principal primary modification type that also have an interest rate concession.

⁽⁵⁾ Trial modifications are granted a delay in payments due under the original terms during the trial payment period. However, these loans continue to advance through delinquency status and accrue interest according to their original terms. Any subsequent permanent modification generally includes interest rate related concessions; however, the exact concession type and resulting financial effect are usually not known until the loan is permanently modified. Trial modifications for the period are presented net of previously reported trial modifications that became permanent in the current period.